Stay updated on Merck & Co. Press Releases
Sign up to get notified when there's something new on the Merck & Co. Press Releases page.

Latest updates to the Merck & Co. Press Releases page
- Check3 days agoChange DetectedThe page adds two biotech news items and removes two financial updates, signaling a focus shift toward health/biotech content. Specifically, CAPVAXIVE vaccine results and Ifinatamab Deruxtecan Breakthrough Therapy news are added, while Merck Q2 results and a dividend announcement are removed.SummaryDifference80%
- Check10 days agoChange DetectedThe webpage has updated its content to reflect new clinical trial results and corporate participation in upcoming events, while removing older news releases and updates.SummaryDifference86%
- Check17 days agoChange DetectedThe webpage has been updated with new information regarding Merck's recent activities and clinical trial results, while several previous announcements about drug applications and acquisitions have been removed.SummaryDifference71%
- Check25 days agoChange DetectedThe page has been updated to include the announcement of Ifinatamab Deruxtecan receiving Breakthrough Therapy Designation by the U.S. FDA for a specific cancer treatment, while a previous announcement regarding Merck's earnings call has been removed.SummaryDifference71%
- Check32 days agoChange DetectedThe page now includes updated information on the effectiveness of KEYTRUDA® in treating muscle-invasive bladder cancer, while the previous recommendation for Merck’s ENFLONSIA™ for RSV prevention has been removed.SummaryDifference72%
- Check46 days agoChange DetectedThe webpage has updated its financial results announcement date and removed a previous investor event notice related to HIV treatment research.SummaryDifference72%
Stay in the know with updates to Merck & Co. Press Releases
Enter your email address, and we'll notify you when there's something new on the Merck & Co. Press Releases page.